Treats overactive bladder with symptoms of urge urinary incontinence, urgency, and…. ANDA 206817, held by Aurobindo Pharma. Solifenacin Succinate.
As of Nov 16, 2026, ANDA 206817 (Solifenacin Succinate), held by Aurobindo Pharma, was first approved by FDA on Dec 27, 2022, with 0 approved supplements and 0 published complete response letters.
Solifenacin succinate tablets are indicated for the treatment of adults with overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Dec 27, 2022 | Original application | Approved | None posted |
| Solifenacin Succinate5MG · tablet;oral | Solifenacin Succinate | Rx |
| Solifenacin Succinate10MG · tablet;oral | Solifenacin Succinate | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters